SecBot SecBot
PRESS-RELEASE ·Filed Mar 24, 2026

PVLA

Palvella Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor the March 31 earnings call for potential updates on clinical progress, cash runway, or funding needs, which could impact valuation given the company's pre-revenue status.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$116.23
T+0 close · Mar 24, 2026 · via day close
Latest settled
−2.69%
T+60 · $113.10
Vs SPY
−17.02%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 24 $116.23entry
  2. T+1 · 8mo ago +3.58%α +3.01% · $120.39
  3. T+5 · 8mo ago +7.24%α +7.67% · $124.65
  4. T+20 · 7mo ago +12.40%α +3.50% · $130.64
  5. T+60 · 5mo ago −2.69%α −17.02% · $113.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics announced it will report its full year 2025 financial results on March 31, 2026, followed by a conference call to discuss the results and provide a corporate update. The press release contains no actual financial data, only logistical details about the upcoming earnings announcement.

Key Facts

  • Palvella Therapeutics will report full year 2025 financial results on March 31, 2026, before market open.
  • Management will host a conference call at 8:30 a.m. ET on March 31, 2026, to discuss results and provide a corporate update.
  • No financial results, guidance, or operational updates were disclosed in this release.
  • Company remains in clinical-stage development with no FDA-approved therapies yet.

Financial Impact

No financial data disclosed in this release

Risk Factors

  • No revenue-generating products; dependent on clinical trial outcomes and future financing.
  • Failure to meet clinical or regulatory milestones could negatively impact stock price.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3261100

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 24, 2026